We are live on
!
Find out more
CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.67B
1-Year Est. Return
89%
This Fund
S&P 500
This Quarter
Est. Return
-2.22%
1 Year Est. Return
+89%
3 Year Est. Return
+264.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.07B
AUM Growth
+$5.91M
(+0.55%)
Cap. Flow
+$69.6M
Cap. Flow
% of AUM
6.48%
Top 10 Holdings %
Top 10 Hldgs %
36.46%
Holding
509
New
13
Increased
172
Reduced
270
Closed
23
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$12.7M |
| 2 |
Amazon
AMZN
|
+$9.6M |
| 3 |
Microsoft
MSFT
|
+$7.09M |
| 4 |
Analog Devices
ADI
|
+$4.96M |
| 5 |
Broadcom
AVGO
|
+$4.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Silver Trust
SLV
|
+$7.41M |
| 2 |
ProShares Ultra Gold
UGL
|
+$6.74M |
| 3 |
Arista Networks
ANET
|
+$6.7M |
| 4 |
Gilead Sciences
GILD
|
+$4.85M |
| 5 |
TSMC
TSM
|
+$4.21M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 36.93% |
| 2 | Healthcare | 24.36% |
| 3 | Consumer Discretionary | 11.82% |
| 4 | Communication Services | 11.17% |
| 5 | Consumer Staples | 4.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
Oric Pharmaceuticals
ORIC
$1.43B
| $79.5K | 0.01% |
14,247
-716
| -5% | -$6.26K |
|
377
SIGA Technologies
SIGA
$206M
| $78.5K | 0.01% |
14,323
-817
| -5% | -$4.84K |
|
|
TRML
378
DELISTED
Tourmaline Bio
TRML
| $78.2K | 0.01% |
5,143
-294
| -5% | -$4.71K |
|
379
Erasca
ERAS
$6.5B
| $77.7K | 0.01% |
56,710
-3,239
| -5% | -$5.56K |
|
380
Altimmune
ALT
$570M
| $77.2K | 0.01% |
15,448
+367
| +2% | +$2.33K |
|
|
ORKA
381
Oruka Therapeutics
ORKA
$7.11B
| $77K | 0.01% |
7,509
+88
| +1% | +$1.1K |
|
382
Sana Biotechnology
SANA
$1.13B
| $75.2K | 0.01% |
44,784
-2,557
| -5% | -$7.15K |
|
|
BCYC
383
Bicycle Therapeutics
BCYC
$284M
| $75K | 0.01% |
8,833
-496
| -5% | -$5.84K |
|
384
CorMedix
CRMD
$557M
| $75K | 0.01% |
12,171
-695
| -5% | -$7.19K |
|
385
EyePoint Inc
EYPT
$1.17B
| $74.2K | 0.01% |
13,690
-782
| -5% | -$5.47K |
|
|
LKFT
386
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
| $73.6K | 0.01% |
2,931
-31
| -1% | -$783 |
|
|
RAPP
387
Rapport Therapeutics
RAPP
$2.29B
| $73.6K | 0.01% |
7,337
-419
| -5% | -$5.44K |
|
388
Regenxbio
RGNX
$720M
| $71.1K | 0.01% |
9,938
-567
| -5% | -$4.22K |
|
389
Stoke Therapeutics
STOK
$2.13B
| $70.7K | 0.01% |
10,624
-607
| -5% | -$5.66K |
|
390
Entrada Therapeutics
TRDA
$299M
| $68.2K | 0.01% |
7,541
-390
| -5% | -$4.86K |
|
391
Cartesian Therapeutics
RNAC
$262M
| $67.2K | 0.01% |
5,098
-291
| -5% | -$5.2K |
|
392
Pacific Biosciences
PACB
$345M
| $67.1K | 0.01% |
56,851
-3,137
| -5% | -$4.81K |
|
393
First Trust Dow Jones Internet Index Fund ETF
FDN
$5.38B
| $66.6K | 0.01% |
+300
| New | +$73.9K |
|
394
First Trust Cloud Computing ETF
SKYY
$3.25B
| $66.5K | 0.01% |
+650
| New | +$77.4K |
|
395
Rigel Pharmaceuticals
RIGL
$782M
| $63.6K | 0.01% |
3,533
-202
| -5% | -$4.1K |
|
396
Maravai LifeSciences
MRVI
$861M
| $62.9K | 0.01% |
28,451
-1,625
| -5% | -$6.42K |
|
|
AUTL
397
Autolus Therapeutics
AUTL
$564M
| $62.3K | 0.01% |
40,200
-2,145
| -5% | -$4.35K |
|
398
Personalis
PSNL
$1.52B
| $62.1K | 0.01% |
17,704
+2,724
| +18% | +$12.9K |
|
399
Allogene Therapeutics
ALLO
$714M
| $61.4K | 0.01% |
42,057
-2,401
| -5% | -$4.53K |
|
400
Amylyx Pharmaceuticals
AMLX
$2.6B
| $60.8K | 0.01% |
17,188
+2,653
| +18% | +$9.44K |
|
Similar funds
HA
JPM
CPO
LCI
GWM
JIP
RMC
GACM
China Universal Asset Management Company's Q1 2025 Portfolio in Review
As of Q1 2025, China Universal Asset Management Company held 509 positions worth $1.07B, up 0.55% from $1.07B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
China Universal Asset Management Company deployed $69.6M of net new capital in Q1 2025, opening 13 new positions and adding to 172 existing holdings. Its largest new stake was VNET Group: 300,000 shares worth $2.46M.
By sector, the portfolio is most concentrated in Technology at 37% of assets, down from 38% a quarter earlier, followed by Healthcare and Consumer Discretionary.
On the sell side, the largest reduction was iShares Silver Trust, an estimated $7.41M trimmed.
- China Universal Asset Management Company's largest Q1 2025 buy was VNET Group: 300,000 shares worth $2.46M.
- China Universal Asset Management Company added most to Apple in Q1 2025, an estimated $12.7M increase.
- China Universal Asset Management Company's biggest Q1 2025 reduction was iShares Silver Trust, cutting an estimated $7.41M.
- China Universal Asset Management Company fully exited Arista Networks in Q1 2025, selling an estimated $6.7M.
- China Universal Asset Management Company's ten largest holdings make up 36% of its $1.07B portfolio in Q1 2025.
- China Universal Asset Management Company opened 13 new positions and closed 23 in Q1 2025.
- China Universal Asset Management Company's portfolio value rose 0.55% quarter-over-quarter to $1.07B.
Based on China Universal Asset Management Company's 13F filing for Q1 2025, filed 30 Apr 2025.